Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Neurogastroenterology and Motility
|
January 29, 2008
Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer
T Hirata, Y Keto, M Nakata, et al.
Digestive Diseases and Sciences
|
April 1, 1997
YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs
H Yuki, A Nishida, A Miyake, et al.
Neuropharmacology
|
June 1, 1995
Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex
H Ito, S Akuzawa, R Tsutsumi, et al.
Chemical & Pharmaceutical Bulletin
|
July 1, 1996
Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists
M Satoh, Y Okamoto, H Koshio, et al.
Alimentary Pharmacology & Therapeutics
|
February 1, 1997
YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo
Y Takinami, H Yuki, A Nishida, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 1, 1994
Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo
A Nishida, K Miyata, R Tsutsumi, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 1, 1994
YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats
A Nishida, Y Takinami, H Yuki, et al.
The American Journal of Physiology
|
November 1, 1995
Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression
A Nishida, A Kobayashi-Uchida, S Akuzawa, et al.
Arzneimittel-Forschung
|
June 3, 1998
Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula
Y Takemoto, H Yuki, A Nishida, et al.
Journal of Medicinal Chemistry
|
January 31, 1997
(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist
G Semple, H Ryder, D P Rooker, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Neurogastroenterology and Motility
|
January 29, 2008
Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer
T Hirata, Y Keto, M Nakata, et al.
Digestive Diseases and Sciences
|
April 1, 1997
YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs
H Yuki, A Nishida, A Miyake, et al.
Neuropharmacology
|
June 1, 1995
Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex
H Ito, S Akuzawa, R Tsutsumi, et al.
Chemical & Pharmaceutical Bulletin
|
July 1, 1996
Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists
M Satoh, Y Okamoto, H Koshio, et al.
Alimentary Pharmacology & Therapeutics
|
February 1, 1997
YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo
Y Takinami, H Yuki, A Nishida, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 1, 1994
Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo
A Nishida, K Miyata, R Tsutsumi, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 1, 1994
YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats
A Nishida, Y Takinami, H Yuki, et al.
The American Journal of Physiology
|
November 1, 1995
Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression
A Nishida, A Kobayashi-Uchida, S Akuzawa, et al.
Arzneimittel-Forschung
|
June 3, 1998
Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula
Y Takemoto, H Yuki, A Nishida, et al.
Journal of Medicinal Chemistry
|
January 31, 1997
(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist
G Semple, H Ryder, D P Rooker, et al.
Page
of 3